Boston Scientific Corp BSX 1 11 shares sunk 8 2 in pre market trade Thursday after the company said it will voluntarily remove its Lotus Valve devices off the market and from clinical trials due to reports of the premature release of a pin that connects the heart valve device to the delivery system The company said it believes the problem is caused by excess tension in the pin mechanism introduced during the manufacturing process and expects to bring the products back to market in Europe and elsewhere in the fourth quarter of this year U S approval of the company s next generation Lotus Edge Valve System is expected before mid 2018 Boston Scientific said Boston Scientific shares have risen 19 9 over the last three months compared with a 7 2 rise in the S P 500 SPX 0 81